Organization
Gustave Roussy and Paris-Saclay University
3 abstracts
Abstract
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario Virgen Macarena, Maria Skłodowska-Curie National Institute of Oncology Center, Poznan University of Medical Sciences and Greater Poland Cancer Center, UPMC Hillman Cancer Center,
Abstract
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).Org: UPMC Hillman Cancer Center, Pittsburgh, PA, Replimune, Inc., Woburn, MA, Gustave Roussy and Paris-Saclay University,
Abstract
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario 12 de Octubre, Charite-Universitaetsmedizin, Berlin, Germany, Chugai Pharmaceutical, Anaveon,